Virus News and Research

Latest Virus News and Research

Gene therapy used for sight restoration also strengthens visual pathways in the brain

Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children's Hospital of Philadelphia, have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.

16 Jul 2015

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence.

16 Jul 2015

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Immunologists from Emory University have identified a distinct set of long-lived antibody-producing cells in the human bone marrow that function as an immune archive.

16 Jul 2015

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

In recent years, researchers have hotly pursued immunotherapy, a promising form of treatment that relies on harnessing and training the body's own immune system to better fight cancer and infection. Now, results of a study led by Johns Hopkins investigators suggests that a device composed of a magnetic column paired with custom-made magnetic nanoparticles may hold a key to bringing immunotherapy into widespread and successful clinical use.

16 Jul 2015

Oxford University performs second phase of experimental Ebola vaccine trial

Oxford University doctors and scientists are performing the second phase of clinical studies of an experimental Ebola vaccine regimen. The study is part of the EBOVAC2 project, a collaborative programme involving the University of Oxford, French Institute of Health and Medical Research as project coordinator, London School of Hygiene & Tropical Medicine, Le Centre Muraz, Inserm Transfert and the Janssen Pharmaceutical Companies of Johnson & Johnson.

15 Jul 2015

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder.

15 Jul 2015

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

Viruses, not bacteria, are the most commonly detected respiratory pathogens in U.S. adults hospitalized with pneumonia, according to a New England Journal of Medicine study released today and conducted by researchers at Centers for Disease Control and Prevention and hospitals in Chicago and Nashville, including Vanderbilt University Medical Center.

15 Jul 2015

Ebola vaccine study begins in Dakar, Senegal

A trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial immunisations started at the Jenner Institute, Oxford University. The announcement comes as a conference in Oxford discusses the global response to Ebola and the implications for future drug and vaccine development.

15 Jul 2015

New report highlights key success in global response to preventing AIDS in women, children

The Elizabeth Glaser Pediatric AIDS Foundation applauds today's announcement from the Joint United Nations Programme on HIV/AIDS that the goal of providing 15 million people with lifesaving antiretroviral therapy (ART) by 2015 has been met nine months ahead of schedule.

14 Jul 2015

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.

13 Jul 2015

Turnstone announces ongoing enrollment of Marabex clinical trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.

12 Jul 2015

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.

11 Jul 2015

Researchers reveal how certain lipids help adenoviruses to enter the cell

Adenoviruses cause numerous diseases, such as eye or respiratory infections, and they are widely used in gene therapy. Researchers from the University of Zurich have now discovered how these viruses penetrate the cells, a key step for infection and gene delivery. The cell unwillingly supports virus entry and infection by providing lipids that are normally used to repair damaged membranes.

10 Jul 2015

TSRI study reveals alternative approach to current anti-HIV strategies

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS.

9 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

Three South Florida research centers receive Campbell Foundation grants for HIV/AIDS studies

New research is taking place all around the world in the fight to find a cure for AIDS. But did you know that some critical research is taking place in our own backyard? That’s why The Campbell Foundation recently provided three South Florida research centers each with $30,000 fast-track grants to assist them with their ground-breaking investigations.

9 Jul 2015

Vanderbilt investigators develop potential antibody treatments against chikungunya

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Vanderbilt University Medical Center's James Crowe, M.D., Ann Scott Carell Professor and director of the Vanderbilt Vaccine Center, and his team are reporting the first large panel of antibody treatments against this disease in the current issue of Cell Host and Microbe.

9 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV.

7 Jul 2015

Study sheds light on how dengue virus adapts, causes outbreaks as it travels

A researcher from The University of Texas Medical Branch at Galveston is an integral member of a collaborative group that is the first to explain the mechanisms that the Dengue virus has developed to optimize its ability to cause outbreaks as it travels across the globe to new places and revisits old ones.

7 Jul 2015

Virus News and Research

Latest Virus News and Research

Gene therapy used for sight restoration also strengthens visual pathways in the brain

Canadian researchers discover how HIV evades the body's antiviral responses

Emory University immunologists identify long-lived antibody-producing cells in bone marrow

Magnetic nanoparticles may hold key to bringing immunotherapy into successful clinical use

Oxford University performs second phase of experimental Ebola vaccine trial

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

New study highlights burden of community-acquired pneumonia hospitalizations among U.S. adults

Ebola vaccine study begins in Dakar, Senegal

New report highlights key success in global response to preventing AIDS in women, children

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Turnstone announces ongoing enrollment of Marabex clinical trial

Envarsus XR receives FDA approval for treatment of kidney transplant recipients

Researchers reveal how certain lipids help adenoviruses to enter the cell

TSRI study reveals alternative approach to current anti-HIV strategies

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Three South Florida research centers receive Campbell Foundation grants for HIV/AIDS studies

Vanderbilt investigators develop potential antibody treatments against chikungunya

New research identifies potential treatment for primary effusion lymphoma

Southern Research receives $22 million to support HIV cure initiative

Study sheds light on how dengue virus adapts, causes outbreaks as it travels

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in